PUBLIC COMPANY
savePFIZER
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults
- —A Study to Learn About the Safety of PENBRAYA During Pregnancy
- phase1A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
- phase2A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- phase3A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- phase1An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
- phase3Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- phase3Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
🐶 Hiring Signal
News
- Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analystsIf confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…biospace · 3h ago
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 9h ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 2d ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 5d ago
- After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosure—have drawn international scrutiny to what appear to be…fiercebiotech · 5d ago
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 5d ago
- Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillThree years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.fiercebiotech · 7d ago
- Post-Hoc: Rewatch the Boston edition of our China Biotech DebateLast week, we hosted the most engaging event I’ve been a part of here at Endpoints News. If you were there, you got to see a showdown of ideas between some of the most important ...endpoints · 7d ago
- BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectationsBridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.biospace · 7d ago
- CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaquesCytoDyn's leronlimab may have struggled to secure approval as an HIV treatment, but research in infant primates has offered fresh hope for the CCR5-targeting antibody's ability to treat the virus.fiercebiotech · 8d ago
comments(0)
5-min edit window · permanent after that